Literature DB >> 11355148

Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas.

M Schiebe1, P Ohneseit, W Hoffmann, R Meyermann, H P Rodemann, M Bamberg.   

Abstract

PURPOSE: Malignant gliomas are the most frequent primary brain tumors. Recent studies defined several genetic markers, which might characterize molecular-biological subsets of glioblastomas with prognostic implications. In the later steps of tumor-progression, deletions on chromosome 11p15 and mutations of the tumor suppressor gene p53 were determined for different malignancies. To elucidate the involvement of 11p15 deletions in the tumorigenesis of malignant gliomas, we analyzed a series of 50 glioblastomas for loss of heterozygosity (LOH).
METHODS: Paired tissue and blood samples from 50 patients with glioblastoma multiforme were included. Microsatellite markers located on 11p15.1-11p15.5 were used for LOH analysis. Additionally, mutation analysis of the tumor suppressor gene p53 was performed, which might correlate with favorable survival in glioblastomas.
RESULTS: The region 11p15.4-5 was deleted heterozygously in 28% of cases representing 15 cM. Twenty-six glioblastomas did not show allelic loss for any locus. Our data revealed close association of LOH 11p15 with p53 mutations, and survival analysis showed a trend indicating better prognosis in glioblastomas characterized by LOH 11p15.
CONCLUSION: In the tumorigenesis of malignant gliomas, p53 mutations and 11p15 deletions seem to indicate a genetic subset of tumors with favorable prognostic value.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355148     DOI: 10.1007/s004320000216

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  7 in total

1.  The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression.

Authors:  Adam M Sonabend; Mukesh Bansal; Paolo Guarnieri; Liang Lei; Benjamin Amendolara; Craig Soderquist; Richard Leung; Jonathan Yun; Benjamin Kennedy; Julia Sisti; Samuel Bruce; Rachel Bruce; Reena Shakya; Thomas Ludwig; Steven Rosenfeld; Peter A Sims; Jeffrey N Bruce; Andrea Califano; Peter Canoll
Journal:  Cancer Res       Date:  2014-01-03       Impact factor: 12.701

2.  The Sjögren's syndrome-associated autoantigen Ro52/TRIM21 modulates follicular B cell homeostasis and immunoglobulin production.

Authors:  S Brauner; M Ivanchenko; G E Thorlacius; A Ambrosi; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2018-10-16       Impact factor: 4.330

Review 3.  Cancer and forensic microsatellites.

Authors:  Karen Page; Eleanor A M Graham
Journal:  Forensic Sci Med Pathol       Date:  2008-02-02       Impact factor: 2.007

4.  Efficient exploration of pan-cancer networks by generalized covariance selection and interactive web content.

Authors:  Teresia Kling; Patrik Johansson; José Sanchez; Voichita D Marinescu; Rebecka Jörnsten; Sven Nelander
Journal:  Nucleic Acids Res       Date:  2015-05-07       Impact factor: 16.971

5.  Decreased expression of haemoglobin beta (HBB) gene in anaplastic thyroid cancer and recovery of its expression inhibits cell growth.

Authors:  M Onda; J Akaishi; S Asaka; J Okamoto; S Miyamoto; K Mizutani; A Yoshida; K Ito; M Emi
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

6.  Loss of heterozygosity of TRIM3 in malignant gliomas.

Authors:  Jean-Louis Boulay; Urs Stiefel; Elisabeth Taylor; Béatrice Dolder; Adrian Merlo; Frank Hirth
Journal:  BMC Cancer       Date:  2009-02-27       Impact factor: 4.430

7.  Transcriptional signature of an adult brain tumor in Drosophila.

Authors:  Thomas Loop; Ronny Leemans; Urs Stiefel; Leandro Hermida; Boris Egger; Fukang Xie; Michael Primig; Ulrich Certa; Karl-Friedrich Fischbach; Heinrich Reichert; Frank Hirth
Journal:  BMC Genomics       Date:  2004-04-16       Impact factor: 3.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.